Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-12-2023 | Lichenoid Pityriasis | Case report

Tozinameran

Pityriasis lichenoides chronica: case report.

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Drago F, et al. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine. Journal of the European Academy of Dermatology and Venereology 36: e979-e981, No. 12, Dec 2022. Available from: URL: http://doi.org/10.1111/jdv.18418 Drago F, et al. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine. Journal of the European Academy of Dermatology and Venereology 36: e979-e981, No. 12, Dec 2022. Available from: URL: http://​doi.​org/​10.​1111/​jdv.​18418
Metadata
Title
Tozinameran
Pityriasis lichenoides chronica: case report.
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51284-3

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Methotrexate

Case report

Thiamazole

Case report

Pembrolizumab

Case report

Empagliflozin